Abstract: The rapidly aging population directly contributes to the increasing cases of neurological disorders. Due to the chronic progressive nature of neurodegeneration, numerous neurological conditions are considered “multifactorial” with systemic metabolic alterations. Even so, treatments for neurological disorders have remained unchanged for the past decades. Recently, metabolic drugs such as metformin and glucagonlike peptide 1 agonists have demonstrated promising health outcomes for neurodegeneration. While the exact mechanisms remain to be elucidated, this promotes the repurposing of antidiabetic drugs for cognitive health and redefines neurological disorders as “neurometabolic” disorders. The complexity of systemically acting drugs lies in determining whether their effects are mediated directly through their actions on the brain or indirectly via their peripheral effects. This perspective focuses on the repurposing of metformin for neurological disorders through the remodeling of the myelin landscape.